Beranda › Leukemia Biphenotypic Akut › South Carolina › Greenville
Uji klinis Leukemia Biphenotypic Akut di Greenville, SC
3 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi sekitar Greenville (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Menerima pesertaFase 2
- BI-LO Charities Children's Cancer Center, Greenville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Menerima pesertaFase 3
- BI-LO Charities Children's Cancer Center, Greenville
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Menerima pesertaFase 1/2
- BI-LO Charities Children's Cancer Center, Greenville
Uji klinis Leukemia Biphenotypic Akut di kota lain
- Seattle, WA15 studi
- Houston, TX11 studi
- New York City, NY10 studi
- Atlanta, GA9 studi
- Durham, NC8 studi
- Memphis, TN7 studi
- Chicago, IL7 studi
- Charlotte, NC6 studi
- Baldwin Park, CA6 studi
- Philadelphia, PA6 studi
- Dallas, TX6 studi
- Aurora, CO6 studi
Studi lain di Greenville
- Kanker Paru Non-Sel Kecil15 studi
- Kanker Payudara12 studi
- Leukemia Mieloid Akut10 studi
- Kanker (semua jenis)9 studi
- Obesitas9 studi
- Kanker Paru9 studi
- Kelebihan Berat Badan8 studi
- Kanker Prostat7 studi
- Kanker Kolorektal7 studi
- Kanker Lambung6 studi
- Penyakit Arteri Perifer5 studi
- Limfoma Burkitt5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.